Litigation Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2013)

Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2013)

Docket		Date Filed	2013-07-02
Court	District Court, S.D. New York	Date Terminated	2014-12-23
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	7,674,799; 7,674,800; 7,683,072; 7,776,314; 8,114,383; 8,337,888
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-07-02				External link to document

Purdue Pharma v. Teva Pharmaceuticals: Litigation Summary, Patent Claims, and Generic OxyContin Entry Risk

Last updated: August 4, 2026

Purdue Pharma sued Teva Pharmaceuticals in the Southern District of New York after Teva filed an abbreviated new drug application seeking approval to market extended-release oxycodone tablets. The dispute concerned Purdue’s abuse-deterrent OxyContin formulation and two patents directed to controlled-release oxycodone dosage forms. The district court rejected Teva’s principal invalidity challenges and found infringement. The case constrained Teva’s ability to launch a competing product before the asserted patents expired. The litigation did not involve a biologic or biosimilar pathway.

What was Purdue Pharma v. Teva Pharmaceuticals about?

Purdue alleged that Teva’s proposed generic extended-release oxycodone product would infringe patents covering controlled-release oxycodone formulations. The case arose under the Hatch-Waxman Act after Teva submitted a Paragraph IV certification stating that the relevant Purdue patents were invalid, unenforceable, or would not be infringed.

Item	Detail
Case	Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc.
Civil action	No. 1:13-cv-04606
Court	U.S. District Court for the Southern District of New York
Plaintiff	Purdue Pharma L.P.
Defendant	Teva Pharmaceuticals USA, Inc.
Product	Extended-release oxycodone tablets, including Purdue’s OxyContin product
Regulatory pathway	ANDA with Paragraph IV certification
Principal patents	U.S. Patent Nos. 7,074,430 and 8,337,888
Core dispute	Patent validity, claim construction, and infringement
Decision	Purdue prevailed on the principal patent claims
Product category	Small-molecule opioid analgesic
Biosimilar relevance	None

The litigation focused on the technical characteristics that made Purdue’s reformulated OxyContin difficult to crush, grind, dissolve, or otherwise manipulate for rapid release or non-oral administration.

What patents did Purdue assert against Teva?

Purdue asserted U.S. Patent Nos. 7,074,430 and 8,337,888. Both patents addressed controlled-release oxycodone formulations and descended from Purdue’s broader patent program for extended-release opioid dosage forms.

U.S. Patent No. 7,074,430

The ’430 patent covered controlled-release oxycodone dosage forms containing oxycodone or a pharmaceutically acceptable salt and a hydrophilic matrix, including high-molecular-weight polyethylene oxide. The claims also addressed release characteristics intended to provide prolonged analgesia.

The patent was important because it linked the formulation’s physical composition to its pharmacokinetic and abuse-deterrent properties. Purdue used those claims to challenge generic formulations designed to provide an equivalent extended-release profile.

U.S. Patent No. 8,337,888

The ’888 patent covered additional controlled-release oxycodone formulations and related abuse-deterrent characteristics. Purdue relied on the patent to protect formulation features that affected mechanical resistance and drug-release behavior.

The asserted claims covered formulation limitations rather than the oxycodone molecule itself. That distinction matters commercially. Oxycodone had long been known, while Purdue’s patent position depended on the formulation, release profile, and abuse-deterrent architecture.

Patent	General subject matter	Role in litigation
7,074,430	Controlled-release oxycodone dosage forms	Asserted against Teva’s ANDA product
8,337,888	Controlled-release and abuse-deterrent oxycodone formulations	Asserted against Teva’s ANDA product

Patent-family information and expiration data should be read together with the Orange Book listing and terminal-disclaimer records. Continuation patents in this family did not necessarily receive independent 20-year terms.

When did the Purdue v. Teva litigation begin?

Purdue filed the action in 2013 after Teva’s ANDA certification created a statutory act of infringement under 35 U.S.C. § 271(e)(2). The filing triggered the Hatch-Waxman litigation stay, which generally prevents FDA approval of the challenged ANDA for 30 months unless the court issues an earlier decision.

The case proceeded through claim construction, fact discovery, expert testimony, and a bench trial. The parties disputed the meaning of key formulation terms, including the scope of the controlled-release matrix and the characteristics required to satisfy the claimed release profile.

Procedural timeline

Date	Event
2013	Purdue filed the patent infringement action against Teva
2014-2016	Claim construction, discovery, and dispositive-motion proceedings
2017	District court issued its principal merits decision
2017 onward	Judgment and post-trial proceedings limited Teva’s ability to market the challenged product before patent expiry
Later period	Generic oxycodone competition developed through other products, authorized-generic arrangements, and separate regulatory approvals

The central reported district-court decision is Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., 2017 WL 2334028 (S.D.N.Y. May 30, 2017).

What did the court decide?

The court rejected Teva’s principal challenges to the asserted claims and found that Teva’s proposed product would infringe the relevant Purdue patent claims. Purdue therefore obtained a favorable judgment preventing Teva from commercially launching the ANDA product while enforceable patent protection remained in place.

The decision addressed several issues:

1. Claim construction. The court interpreted formulation and release-profile limitations in the asserted claims.
2. Validity. Teva challenged the claims on grounds including obviousness and anticipation.
3. Infringement. The court compared Teva’s proposed ANDA formulation with the construed claims.
4. Hatch-Waxman remedies. The judgment affected FDA approval and the timing of generic entry.

The case illustrates the commercial value of formulation patents. Purdue did not need to own the underlying oxycodone molecule to delay generic competition. It relied on patents covering the delivery system and abuse-deterrent performance of the finished dosage form.

Did Teva file a Paragraph IV challenge?

Yes. The litigation was based on Teva’s Paragraph IV certification. That certification asserted that Purdue’s patents were invalid, unenforceable, or would not be infringed by Teva’s proposed generic product.

A Paragraph IV filing creates two competing effects:

• It gives the generic applicant a mechanism to challenge listed patents before launch.
• It gives the branded company a statutory infringement claim and, generally, a 30-month stay of FDA approval.

The case did not involve a simple “wait-and-see” Paragraph III certification. Teva pursued early market entry by contesting Purdue’s patent estate.

How strong was Purdue’s patent estate?

Purdue’s estate was strong against the specific Teva product presented to the court. The district court’s infringement ruling meant that Teva faced a substantial launch barrier before expiration of the asserted patents.

The estate had several strengths:

Formulation-specific claim scope

The patents targeted the finished dosage form, including the matrix and release behavior. Those limitations made a design-around more difficult than a simple change in labeling or tablet strength.

Technical infringement evidence

The case required detailed analysis of Teva’s proposed formulation and its release characteristics. Formulation patents can be difficult to challenge because the infringement analysis may depend on laboratory testing, expert interpretation, and the interaction of multiple excipients.

Orange Book leverage

Listed patents can delay FDA approval after a Paragraph IV filing. Even where a generic applicant has a credible invalidity argument, litigation imposes significant timing and launch risk.

Limits on estate strength

The patents did not provide permanent exclusivity over oxycodone. They covered particular controlled-release and abuse-deterrent formulations. A competitor could pursue a non-infringing formulation, rely on a different release technology, or enter after expiration.

When did the asserted Purdue patents expire?

The ’430 and ’888 patents were members of the same broader controlled-release oxycodone patent family, and their effective patent-term analysis was tied to the family’s priority and continuation history. Public patent records generally place the relevant expiration period in 2025, subject to patent-term adjustment, terminal disclaimers, and Orange Book records.

Patent	Publicly reported expiration period	Commercial implication
U.S. 7,074,430	2025	Barrier to the specifically covered formulation until expiration, subject to enforceability and regulatory status
U.S. 8,337,888	2025	Same family-era protection for additional controlled-release claims
Later Purdue formulation patents	Varies by patent	Could create separate barriers for particular products or strengths

A patent expiration date does not automatically produce generic entry. FDA approval, product-specific claims, pediatric exclusivity, injunctions, regulatory review, and the generic applicant’s formulation all affect launch timing.

What was the FDA and Orange Book significance?

The FDA Orange Book identifies approved drug products and patent information submitted by the NDA holder. Purdue’s listed patents gave the company a statutory basis to sue an ANDA applicant making a Paragraph IV certification.

The Orange Book functioned as the regulatory bridge between Purdue’s patent rights and Teva’s ANDA:

1. Purdue listed patents associated with the approved extended-release oxycodone product.
2. Teva submitted an ANDA referencing the approved product.
3. Teva certified against the listed patents.
4. Purdue sued within the Hatch-Waxman framework.
5. The litigation affected the timing of FDA approval and commercial launch.

Orange Book listing did not establish that every listed claim was valid or infringed. The court still had to construe the claims, assess validity, and determine infringement.

Did the case involve a settlement agreement?

The reported core proceeding is associated with a court judgment in Purdue’s favor rather than a public settlement that replaced the merits decision. The case record should be distinguished from other Purdue, Teva, Actavis, and oxycodone disputes, including authorized-generic arrangements and later opioid-related commercial agreements.

No broad settlement-based launch date should be inferred from the existence of a Paragraph IV case. Generic entry could occur through:

• expiration of the asserted patents;
• a successful invalidity or non-infringement challenge;
• a license;
• an authorized-generic arrangement;
• a redesigned, non-infringing formulation; or
• a separate FDA approval pathway.

Which companies challenged Purdue’s OxyContin patents?

Teva was one of the principal ANDA challengers involved in the reported case. Other generic-drug companies pursued oxycodone products or participated in separate patent and regulatory disputes involving OxyContin and its abuse-deterrent formulation.

The competitive landscape included:

Company type	Typical strategy
Generic manufacturers	Paragraph IV challenge, formulation design-around, or post-expiration entry
Purdue and affiliates	Orange Book listings, infringement litigation, continuation patents, and formulation claims
Authorized-generic suppliers	Launch under a license or commercial arrangement with the branded company
Competing opioid manufacturers	Alternative extended-release products or different dosage technologies

The existence of another generic oxycodone product did not necessarily establish freedom to market the same abuse-deterrent formulation. Different products could have different patent exposure.

What generic entry risks did Teva face?

Teva faced four principal risks.

Launch injunction

A finding of infringement could prevent commercial launch until the relevant patents expired or the parties reached an enforceable resolution.

Regulatory delay

The Hatch-Waxman stay could delay FDA approval independently of the merits. A court decision favorable to Purdue removed Teva’s principal route to early approval and launch.

Formulation redesign

A redesigned product could avoid one patent but create new technical, regulatory, and manufacturing issues. A change in excipients or matrix architecture might affect dissolution, abuse-deterrent performance, bioequivalence, or labeling.

Damages and litigation cost

Although ANDA litigation generally centers on injunctive relief before launch, an at-risk launch could expose a generic company to damages and further injunctive proceedings.

How did this case affect Purdue’s revenue exposure?

The litigation protected Purdue’s ability to sell reformulated OxyContin without direct competition from Teva’s challenged product during the enforceable patent period. The commercial value was material because extended-release oxycodone had been a major Purdue product.

Revenue protection was limited by several factors:

• opioid prescribing restrictions;
• state and federal enforcement actions;
• payer controls and utilization management;
• public-health-related demand changes;
• competing extended-release opioid products;
• authorized-generic competition; and
• Purdue’s later bankruptcy and restructuring process.

Patent success therefore did not guarantee continued product revenue. It reduced one form of generic-entry risk while broader legal and commercial pressures continued.

Did Purdue v. Teva involve biosimilars?

No. The case involved a conventional small-molecule generic under the ANDA pathway. Biosimilar concepts under the Biologics Price Competition and Innovation Act were not relevant.

The distinction matters because:

• ANDA litigation relies on Orange Book patents and Hatch-Waxman procedures.
• Biosimilar litigation relies on the Purple Book, biologic exclusivity, and the Biologics Price Competition and Innovation Act.
• Oxycodone is a small molecule, not a biologic.
• No biosimilar interchangeability analysis applied.

What is the current litigation status?

The merits dispute was resolved through the district court’s reported decision and resulting judgment. The case is not best characterized as an unresolved pending Paragraph IV trial. The practical effect of the decision was to prevent Teva from launching the challenged generic product before the relevant Purdue patent protections expired, unless another legal or commercial route became available.

The case should not be confused with later opioid litigation involving Purdue’s bankruptcy, state enforcement actions, federal claims, or settlements concerning opioid-related conduct. Those proceedings addressed different claims and parties.

Key Takeaways

• Purdue sued Teva in 2013 over an ANDA for extended-release oxycodone.
• The principal patents were U.S. Patent Nos. 7,074,430 and 8,337,888.
• Teva’s Paragraph IV certification triggered Hatch-Waxman litigation.
• The Southern District of New York ruled for Purdue on the principal infringement and validity issues.
• Purdue’s protection came from formulation and abuse-deterrent claims, not from ownership of the oxycodone molecule.
• The asserted patents were generally associated with an expiration period in 2025.
• The dispute was a small-molecule generic case, not a biosimilar case.
• Teva faced launch, regulatory, redesign, and litigation-cost risks.
• The decision protected Purdue from the specific Teva ANDA product during the enforceable patent period, but it did not block every possible oxycodone competitor.

FAQs

What was the main patent in Purdue Pharma v. Teva?

The litigation principally involved U.S. Patent Nos. 7,074,430 and 8,337,888, which covered controlled-release oxycodone and abuse-deterrent formulation characteristics.

Did Teva win its Paragraph IV challenge?

No. The district court ruled in Purdue’s favor on the principal claims asserted against Teva’s proposed product.

Could Teva launch a different oxycodone formulation?

Potentially, but a different product would require separate infringement, bioequivalence, regulatory, and commercial analysis. The judgment applied to the product and claims litigated in the case.

Did Purdue’s patents cover all generic oxycodone products?

No. The patents covered specified controlled-release and abuse-deterrent formulations. Immediate-release oxycodone and non-infringing extended-release products required separate analysis.

Was the Purdue v. Teva case part of Purdue’s bankruptcy litigation?

No. The patent case was a Hatch-Waxman infringement action. Purdue’s later bankruptcy and opioid-related proceedings involved different legal issues and broader sets of parties.

References

1. U.S. District Court for the Southern District of New York. (2017). Purdue Pharma L.P. v. Teva Pharmaceuticals USA, Inc., No. 1:13-cv-04606, 2017 WL 2334028 (S.D.N.Y. May 30, 2017).

2. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,074,430: Controlled release oxycodone formulations.

3. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,337,888: Abuse-deterrent controlled release dosage forms.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

5. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).